Faculty of Informatics and Management, University of Hradec Kralove, Rokitanskeho 62, 50003, Hradec Kralove, Czech Republic.
Biomedical Research Centrum, University Hospital Hradec Kralove, Hradec Kralove, Rokitanskeho 62, 50003, Hradec Kralove, Czech Republic.
Curr Alzheimer Res. 2018;15(14):1277-1282. doi: 10.2174/1567205015666180925110222.
The incidence of both diabetes and Alzheimer's disease (AD) is increasing and is becoming a social and economic threat worldwide. Recent research studies indicate that both diseases share some pathophysiological features and that specifically, Type 2 Diabetes Mellitus (T2DM) is a risk factor of Alzheimer's disease. The aim of this study is to explore the relationship between diabetes mellitus and AD, explore the efficacy of selected drugs on patients with diabetes and AD, and compare the relative risk of diabetes for Alzheimer's disease within different clinical studies. The method of literature search in several acknowledged databases such as Web of Science, Elsevier Science Direct, PubMed and Scopus in the period from 2000 to 2015 for the following keywords: "Alzheimer's AND disease AND diabetes AND mellitus" was used. The identified studies were divided into two basic groups, based on their focus: efficacy of the selected drugs on patients suffering from AD and diabetes, and a link between diabetes and AD; as diabetes is seen as a risk factor of AD. The findings of this study confirm that there is a close and direct link between diabetes and AD, which indicates that there is a need for early diagnosis of metabolic syndrome, insulin resistance, and T2DM. In fact, the reviewed clinical trials have proved an increase in the risk of AD. However, the values of this risk are relatively low. The results also illustrate that both pharmacological (e.g., the antidiabetic drugs together with insulin dosing) and nonpharmacological (e.g., being intensively engaged in physical activities) treatments can have a positive effect. The results of this study confirm that diabetes and AD are not independent disorders since they share some common pathophysiological mechanisms. In addition, more clinical randomized control trials are needed to explore the efficacy of both pharmacological and non-pharmacological approaches to the treatment of T2DM and AD.
糖尿病和阿尔茨海默病(AD)的发病率都在增加,并且正在成为全球范围内的社会和经济威胁。最近的研究表明,这两种疾病具有一些共同的病理生理特征,特别是 2 型糖尿病(T2DM)是 AD 的一个危险因素。本研究旨在探讨糖尿病与 AD 之间的关系,探索选定药物对糖尿病和 AD 患者的疗效,并比较不同临床研究中糖尿病对 AD 的相对风险。使用了在几个公认的数据库(例如 Web of Science、Elsevier Science Direct、PubMed 和 Scopus)中从 2000 年到 2015 年搜索以下关键字的文献搜索方法:“阿尔茨海默氏病 AND 疾病 AND 糖尿病 AND 糖尿病”。根据其重点,将已识别的研究分为两个基本组:患有 AD 和糖尿病的患者的选定药物的疗效,以及糖尿病和 AD 之间的联系;因为糖尿病被视为 AD 的危险因素。本研究的结果证实了糖尿病与 AD 之间存在密切而直接的联系,这表明需要早期诊断代谢综合征、胰岛素抵抗和 T2DM。实际上,已审查的临床试验已证明 AD 的风险增加。但是,这种风险的价值相对较低。结果还表明,药理学(例如,抗糖尿病药物与胰岛素剂量一起)和非药理学(例如,积极进行体育锻炼)治疗都可以产生积极的效果。本研究的结果证实了糖尿病和 AD 不是独立的疾病,因为它们具有一些共同的病理生理机制。此外,还需要更多的临床随机对照试验来探索药理学和非药理学方法治疗 T2DM 和 AD 的疗效。